Dr. Normanno on Using Circulating Tumor DNA for EGFR Detection

Video

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).

An analysis of the ASSESS trial examined whether patient disease or demographic characteristics influenced the detection of EGFR mutations in plasma through extraction of circulating tumor DNA.

The analysis found increased sensitivity of EGFR mutation detection in plasma associated with increasing number of metastases and severity of tumor burden. EGFR mutation detection in plasma was also significantly higher in patients aged less than 65 years old compared with older patients.

However, it still unknown why biological mechanisms underline why some patients have an increased sensitivity of EGFR mutation detection in plasma while others do not, says Normanno. These mechanisms need to better identified before treatment changes are made based on circulating tumor DNA testing, he adds.

<<<

View more from the 2016 European Lung Cancer Conference

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.